Skip to contentC
Castle Biosciences Inc
C
CSTLCastle Biosciences Inc Q1 2022 · 10-Q
Revenue$26.85M$26.85M+17.7% vs Q1 2021 Net Income-$24.62M-$24.62MN/M vs Q1 2021 EPS Diluted-$0.97-$0.97N/M vs Q1 2021 Operating Income-$24,516,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Castle Biosciences Inc · CIK 1447362 · Engraved from SEC EDGAR
Free Cash Flowderived-$21,832,000N/M Margins · derivedOperating margin-91.3%−72.5 pt vs Q1 2021
Net margin-91.7%−72.9 pt vs Q1 2021
ended Mar 31, 2022 · filed May 9, 2022 · 39 d after period end